Adicet Bio, Inc.

Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company's approach involves engineering gamma delta T cells with chimeric antigen receptors (CARs) to create off-the-shelf cellular therapies. This allogeneic model distinguishes Adicet's platform from autologous CAR-T approaches, potentially enabling standardized manufacturing and broader patient access.

The company's lead candidate, ADI-001, is an allogeneic gamma delta CAR-T cell therapy targeting CD20, currently in Phase I clinical development for autoimmune diseases and relapsed/refractory B-cell non-Hodgkin's lymphoma. ADI-270, a second program, represents an armored gamma delta CAR-T cell candidate designed to address CD70-positive solid tumors and hematological malignancies, with renal cell carcinoma as an initial indication.

Adicet Bio operates as a private development-stage entity with no disclosed revenue streams. The company maintains a workforce of approximately 152 full-time employees and is headquartered in Boston, Massachusetts. The organization was founded in 2014 and incorporated in Delaware.